You are here
Articles on Targeted Therapy in Gastric Cancer
This section of the Advances in Gastrointestinal Cancer Resource Centre focuses on the latest clinically relevant findings in targeted therapy for gastrointestinal cancers. The peer-reviewed articles available here have been independently selected, and several commented upon, by members of the Editorial Board. Many of the articles are freely available for downloading.
Focusing initially on gastric cancer, these pages will provide new content each month to help you stay abreast of recent scientific developments in this area.
Exciting findings from genomic sequencing have opened up the therapeutic possibilities for gastric cancer, particularly that in advanced stages, and made targeted therapy possible. Molecular signatures that appear to be associated with a poor prognosis or aggressive disease and may be amenable to targeting in gastric cancer include HER-2, EGFR, VEGF, HGF and the MET pathway, and mTOR.1
Targeted therapies already approved in the USA and Europe for use in gastric cancer include trastuzumab (which targets HER-2) and ramucirumab (which targets VEGF). Many others have been or continue to be under study in clinical trials, including the HER-2 inhibitors lapatinib and pertuzumab, the EGFR inhibitor panitumumab, the VEGF inhibitors apatinib and aflibercept. Much of the research in this area is examining combinations of these targeted agents with each other or with chemotherapy.
To stay abreast of the most recent developments and clinical trial findings in the use of targeted therapy for the treatment of gastrointestinal cancers, please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.
EGFR, epidermal growth factor receptor; HER-2, human epidermal growth factor receptor 2; HGF, hepatocyte growth factor; mTOR, mammalian target of rapamycin; VEGF, vascular endothelial growth factor.
1. Qiu M-Z, Xu R-H. The progress of targeted therapy in advanced gastric cancer. Biomarker Res. 2013;1:32.
Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab
Fuchs CS, Tabernero J, Tomášek J, Chau I, Melichar B, Safran, et al.Br J Cancer 2016;115:974-982.
Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L.World J Gastroenterol 2016 Jul 14;22(26):5879-87.
EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus
Birkman E-M, Ålgars A, Lintunen M, Ristamäki R, Sundström J, Carpén OBMC Cancer. 2016; 16: 406.
Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacopuzzi S, Aprile G, et al.Clin Cancer Res 2016 Jun 7 [Epub ahead of print]
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, et alBr J Cancer. 2016 Mar 1;114(5):505-9
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study
Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, et alCancer. 2016 May 1;122(9):1434-43.
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer
Kataoka H, Mori Y, Shimura T, Nishie H, Natsume M, Mochizuki H, et al.Cancer Chemother Pharmacol. 2016 Mar 22. [Epub ahead of print]
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
Kim ST, Lee J, Lee SJ, Park SH, Jung SH, Park YS, Lim HY, Kang WK, Park JOOncotarget. 2016 Mar 18. [Epub ahead of print]
Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial
Hacker UT, Escalona-Espinosa L, Consalvo N, Goede V, Schiffmann L, Scherer SJ, et alBr J Cancer. 2016 Apr 12;114(8):855-62
Yvonne L.E. Ang, Wei Peng Yong, Patrick Tan
Critical Reviews in Oncology/Hematology, April 2016, Pages 141 - 146